A Study Comparing Two Mandibular Advancement Devices in the Treatment of Sleep Apnea

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorZiekenhuis Oost-Limburg

About this trial

The goal of this randomised, controlled cross-over study is to compare two mandibular repositioning devices (MRA) already on the market in the treatment of mild-to-moderate obstructive sleep apnea.

Patiënt will test the first MRA for 3 months, after a wash out period of 2 weeks they will test the second MRA for 3 months. It will be randomised what type of MRA will be tested first and second.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Provide signed and dated informed consent

Males or females aged 18 and above

Apnea-Hypopnea Index (AHI) between 5 and 30 events per hour diagnosed by a polysomnography

Previous surgery on the upper airways

Disqualifiers

None

Trial design

Design model

Crossover

Treatments tested in this trial

  • Polygraphy

    Diagnostic test

    Polygraphy will be caried out at the patients home to evaluate each MRA after 3 monhts

  • Questionaire

    Other intervention

    Epworth Sleepiness Scale o Johns, Murray W. "A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale." Sleep, vol. 14, no. 6, 1991, pp. 540-545.

  • Questionaire

    Other intervention

    Patient experience questionnaire o Ng, E.T., Perez-Garcia, A., en Lagravère-Vich, M.O. "Development and Initial Validation of a Questionnaire to Measure Patient Experience with Oral Appliance Therapy." Journal of Clinical Sleep Medicine, vol. 19, nr. 8, 1 aug. 2023, pp. 1437-1445. doi: 10.5664/jcsm.10562. PMID: 37082817; PMCID: PMC10394373

  • Question

    Other intervention

    Patient final choice of preferred MRA

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: MRA1MRA2Experimental treatment 3 interventions
Group B: MRA2MRA1Experimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

AHI

Improvement of AHI (apnea-hypopnea index), measured by polygraphy before treatment and after treatment with each MRA. The goal of the mandibular advancement device is to reduce the number of apneas and hypopneas per hour, apneas are periods when a person stops breathing and hypopneas are instances where airflow is blocked, causing shallow breathing. This is measured by a polygraphy-test overnight at the patiënts home.

Time frame
3 monthts after use of first MRA (mandibular advancement device), 3 months after use of second MRA (mandibular advancement device)

Secondary outcomes

1

Peripheral oxygen saturation 1

Measured by polygraphy * Average saturation (measured in %) * Lowest saturation (measured in %) Oxygen saturation in percent is the fraction of oxygen-saturated haemoglobin relative to total haemoglobin (unsaturated + saturated) in the blood \* 100%

Time frame
3 monthts after use of first MRA, 3 months after use of second MRA
2

Peripheral oxygen saturation 2

Measured by polygraphy o Oxygen desaturation index \>3% (events/h) Desaturation episodes are defined as a decrease in the mean oxygen saturation of ≥3% for more than 10 seconds per hour

Time frame
3 monthts after use of first MRA, 3 months after use of second MRA
3

Peripheral oxygen saturation 3

Measured by polygraphy o Total duration with saturation \< 90% The percentage of cumulative time with oxygen saturation below 90% in total sleep time.

Time frame
3 monthts after use of first MRA, 3 months after use of second MRA
4

ESS

Epworth Sleepiness Scale (questionaire) The minimum value is 0 and the maximum value is 24. A higher score means a worse outcome, indicating more excessive daytime sleepiness. The Epworth Sleepiness Scale is scored by adding up the individual scores for each of the eight questions. Each question is rated on a scale of 0 to 3, with 0 being "no chance of dozing" and 3 being "high chance of dozing." ter daytime sleepiness. Score range Interpretation 0-5 Lower normal daytime sleepiness 6-10 Normal daytime sleepiness 11-12 Mild excessive daytime sleepiness 13-15 Moderate excessive daytime sleepiness 16-24 Severe excessive daytime sleepiness

Time frame
3 monthts after use of first MRA, 3 months after use of second MRA

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: